Prescient Therapeutics (ASX:PTX) has reported a net loss after tax of A$7.0 million for the fiscal year, compared to a loss of A$5.1 million from the previous year.
Prescient Therapeutics is a clinical-stage oncology company dedicated to pioneering treatments that can provide better outcomes for patients.
Global online trading services company, Plus500:
Plus500 trading platform allows you to trade shares from all popular markets such as USA, UK, Germany and more, with leverage and low spreads. Using our advanced trading tools, you can also control your profits and losses.
Plus500AU Pty Ltd, AFSL #417727 issued by Australian Securities and Investments Commission. Based in Sydney.
Receive whispers every day in your inbox.
